Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · IEX Real-Time Price · USD
6.72
+0.05 (0.83%)
Apr 19, 2024, 10:43 AM EDT - Market open
Verve Therapeutics Stock Forecast
VERV's stock price has decreased by -58.14% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 35.33, with a low estimate of 22 and a high estimate of 55. The average target predicts an increase of 426.14% from the current stock price of 6.72.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VERV stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $56 → $40 | Strong Buy | Maintains | $56 → $40 | +495.68% | Apr 3, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +421.22% | Feb 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $22 | Hold | Reiterates | $22 | +227.62% | Sep 13, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $22 | Hold | Reiterates | $22 | +227.62% | Aug 29, 2023 |
| Guggenheim | Guggenheim | Strong Buy Maintains $56 → $55 | Strong Buy | Maintains | $56 → $55 | +719.06% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
14.75M
from 11.76M
Increased by 25.40%
Revenue Next Year
9.93M
from 14.75M
Decreased by -32.64%
EPS This Year
-2.97
from -3.12
EPS Next Year
-3.22
from -2.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.1M | 25.8M | 47.3M | 31.5M | 183.8M |
| Avg | 14.7M | 9.9M | 15.2M | 19.0M | 84.1M |
| Low | n/a | n/a | n/a | 7.8M | 12.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 275.1% | 75.2% | 375.7% | 106.8% | 865.1% |
| Avg | 25.4% | -32.6% | 53.4% | 25.0% | 341.8% |
| Low | - | - | - | -48.5% | -37.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.52 | -2.84 | -3.03 | -4.41 | -3.55 |
| Avg | -2.97 | -3.22 | -3.48 | -4.55 | -3.85 |
| Low | -3.40 | -3.68 | -3.71 | -4.78 | -4.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.